| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Biochemistry and Microbiology, University of St Andrews, St Andrews, Fife KY16 9AL, U.K.
The adenovirus (Ad) hexon contains both group- and type-specific antigenic determinants. To identify the latter, peptides were synthesized corresponding to residues 281 to 292 from loop 1 and 441 to 455 from loop 2 of the Ad2 hexon. These sequences display type-specific variation and have been shown by X-ray crystallography to be present on the surface of the virion. Antisera raised against the peptides bound both peptide and the native hexon in ELISA, and blocked virus infectivity, as determined by immunofluorescence or neutralization assays. The loop 1 peptide was shown to inhibit binding of the corresponding antiserum to the native hexon in ELISA and to abolish its neutralizing activity. Neither the loop 1- nor loop 2-specific antiserum neutralized the infectivity of Ad4 or Ad40. Neutralization did not appear to result from aggregation of virus particles and thus their inability to attach to the cell, because virions treated with immune serum were internalized to the same extent as those treated with preimmune serum. Examination of the immune response elicited by Ad2 infection revealed that antibodies directed against the L1 and L2 epitopes were also present in human serum. Thus, the variable regions exposed on the surface of the Ad2 hexon represent type-specific neutralizing antigenic determinants.
Received 25 November 1991;
accepted 20 January 1992.
This article has been cited by other articles:
|
|
 |
|
  J. G. Smith, A. Cassany, L. Gerace, R. Ralston, and G. R. Nemerow Neutralizing Antibody Blocks Adenovirus Infection by Arresting Microtubule-Dependent Cytoplasmic Transport J. Virol., July 1, 2008; 82(13): 6492 - 6500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. C. Nwanegbo, E. G. Romanowski, Y. J. Gordon, and A. Gambotto Efficacy of Topical Immunoglobulins against Experimental Adenoviral Ocular Infection Invest. Ophthalmol. Vis. Sci., September 1, 2007; 48(9): 4171 - 4176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Appaiahgari, R. M. Pandey, and S. Vrati Seroprevalence of Neutralizing Antibodies to Adenovirus Type 5 among Children in India: Implications for Recombinant Adenovirus-Based Vaccines Clin. Vaccine Immunol., August 1, 2007; 14(8): 1053 - 1055. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Pichla-Gollon, M. Drinker, X. Zhou, F. Xue, J. J. Rux, G.-P. Gao, J. M. Wilson, H. C. J. Ertl, R. M. Burnett, and J. M. Bergelson Structure-Based Identification of a Major Neutralizing Site in an Adenovirus Hexon J. Virol., February 15, 2007; 81(4): 1680 - 1689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. C. Lemckert, J. Grimbergen, S. Smits, E. Hartkoorn, L. Holterman, B. Berkhout, D. H. Barouch, R. Vogels, P. Quax, J. Goudsmit, et al. Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity. J. Gen. Virol., October 1, 2006; 87(Pt 10): 2891 - 2899. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. McConnell, X. Danthinne, and M. J. Imperiale Characterization of a permissive epitope insertion site in adenovirus hexon. J. Virol., June 1, 2006; 80(11): 5361 - 5370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Sumida, D. M. Truitt, A. A. C. Lemckert, R. Vogels, J. H. H. V. Custers, M. M. Addo, S. Lockman, T. Peter, F. W. Peyerl, M. G. Kishko, et al. Neutralizing Antibodies to Adenovirus Serotype 5 Vaccine Vectors Are Directed Primarily against the Adenovirus Hexon Protein J. Immunol., June 1, 2005; 174(11): 7179 - 7185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Varghese, Y. Mikyas, P. L. Stewart, and R. Ralston Postentry Neutralization of Adenovirus Type 5 by an Antihexon Antibody J. Virol., November 15, 2004; 78(22): 12320 - 12332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Sumida, D. M. Truitt, M. G. Kishko, J. C. Arthur, S. S. Jackson, D. A. Gorgone, M. A. Lifton, W. Koudstaal, M. G. Pau, S. Kostense, et al. Neutralizing Antibodies and CD8+ T Lymphocytes both Contribute to Immunity to Adenovirus Serotype 5 Vaccine Vectors J. Virol., March 15, 2004; 78(6): 2666 - 2673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Nwanegbo, E. Vardas, W. Gao, H. Whittle, H. Sun, D. Rowe, P. D. Robbins, and A. Gambotto Prevalence of Neutralizing Antibodies to Adenoviral Serotypes 5 and 35 in the Adult Populations of The Gambia, South Africa, and the United States Clin. Vaccine Immunol., March 1, 2004; 11(2): 351 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Hong, N. A. Habib, L. Franqueville, S. Jensen, and P. A. Boulanger Identification of Adenovirus (Ad) Penton Base Neutralizing Epitopes by Use of Sera from Patients Who Had Received Conditionally Replicative Ad (Addl1520) for Treatment of Liver Tumors J. Virol., October 1, 2003; 77(19): 10366 - 10375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Bernal, S. Sharma, B. K. Gardner, J. T. Douglas, J. M. Bergelson, S. M. Dubinett, and R. K. Batra Soluble Coxsackievirus Adenovirus Receptor Is a Putative Inhibitor of Adenoviral Gene Transfer in the Tumor Milieu Clin. Cancer Res., June 1, 2002; 8(6): 1915 - 1923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Soudais, S. Boutin, S. S. Hong, M. Chillon, O. Danos, J. M. Bergelson, P. Boulanger, and E. J. Kremer Canine Adenovirus Type 2 Attachment and Internalization: Coxsackievirus-Adenovirus Receptor, Alternative Receptors, and an RGD-Independent Pathway J. Virol., November 15, 2000; 74(22): 10639 - 10649. [Abstract] [Full Text]
|
|
|
|
|
|
K. Höfling, S. Tracy, N. Chapman, K.-S. Kim, and J. Smith Leser Expression of an Antigenic Adenovirus Epitope in a Group B Coxsackievirus J. Virol., May 15, 2000; 74(10): 4570 - 4578. [Abstract] [Full Text]
|
|
|
|
|
|
A. Akalu, H. Liebermann, U. Bauer, H. Granzow, and W. Seidel The Subgenus-Specific C-Terminal Region of Protein IX Is Located on the Surface of the Adenovirus Capsid J. Virol., July 1, 1999; 73(7): 6182 - 6187. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Takeuchi, N. Itoh, E. Uchio, K. Aoki, and S. Ohno Serotyping of Adenoviruses on Conjunctival Scrapings by PCR and Sequence Analysis J. Clin. Microbiol., June 1, 1999; 37(6): 1839 - 1845. [Abstract] [Full Text]
|
|
|
|
|
|
E. Vigne, I. Mahfouz, J.-F. Dedieu, A. Brie, M. Perricaudet, and P. Yeh RGD Inclusion in the Hexon Monomer Provides Adenovirus Type 5-Based Vectors with a Fiber Knob-Independent Pathway for Infection J. Virol., June 1, 1999; 73(6): 5156 - 5161. [Abstract] [Full Text]
|
|
|
|
|
|
J. G. D. Gall, R. G. Crystal, and E. Falck-Pedersen Construction and Characterization of Hexon-Chimeric Adenoviruses: Specification of Adenovirus Serotype J. Virol., December 1, 1998; 72(12): 10260 - 10264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Gahery-Segard, F. Farace, D. Godfrin, J. Gaston, R. Lengagne, T. Tursz, P. Boulanger, and J.-G. Guillet Immune Response to Recombinant Capsid Proteins of Adenovirus in Humans: Antifiber and Anti-Penton Base Antibodies Have a Synergistic Effect on Neutralizing Activity J. Virol., March 1, 1998; 72(3): 2388 - 2397. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
